Recent news about HIV biomedical prevention research has been a mixed bag: very encouraging results from long-acting pre-exposure prophylaxis (PrEP) trials, but a disappointing lack of significant protection achieved with experimental HIV vaccines. Furthermore, the entire research effort has had to wrestle with the impact of the COVID-19 pandemic.

On September 14 2021, Abraham Johnson, TAG’s Community Engagement Officer, presented this webinar with Carl Dieffenbach, Director of the Division of AIDS at the National Institute for Allergy and Infectious Diseases (NIAID), where he provided an update on the future of biomedical HIV prevention research.